Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistanceAishath Naeem, Jennifer R. Brown, Mauno Vihinen et al.|Blood Advances|2022Cited by 79
A T cell inflammatory phenotype is associated with autoimmune toxicity of the PI3K inhibitor duvelisib in chronic lymphocytic leukemiaDeepti Gadi, Jennifer R. Brown, Alec Griffith et al.|Leukemia|2021Cited by 20